Chi Lin, MD
Enriched profileProfessor and Vice Chair of Research, Department of Radiation Oncology, UNMC · University of Nebraska Medical Center
Chi Lin is Professor and Vice Chair of Research, Department of Radiation Oncology, UNMC at University of Nebraska Medical Center. OpenAlex indexes 219 publications with 3,021 citations (h-index 28); ClinicalTrials.gov lists 24 registered studies with this person as an investigator.
Data verified 26 Oct 2026
Overview
Updated 27 Oct 2026
Chi Lin, MD, is Professor and Vice Chair of Research, Department of Radiation Oncology, UNMC at University of Nebraska Medical Center. The public record shows 219 publications with 3,021 citations (h-index 28), centered on Advanced Radiotherapy Techniques, Pancreatic and Hepatic Oncology Research, Colorectal Cancer Surgical Treatments. It also documents an investigator role on 24 registered clinical trials, industry payments reported by 3 companies, 1 NIH-funded awards (2022–2026).
- Most recent indexed publication: 2024 · Hepatic oncology
- Top research focus: Advanced Radiotherapy Techniques
- 24 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 27 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 72.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 26 Oct 2026
Listed as an investigator on 24 registered studies on ClinicalTrials.gov. The most recent:
- Health Diet Education on Nutrition Literacy and Behavior
Sponsor: En-Chi Chiu
- Study of CHO-A04 in Advanced Solid Tumors
Sponsor: Cho Pharma Inc.
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Sponsor: NRG Oncology
Industry payments
Updated 26 Oct 2026
3 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- HISTOSONICS, INC.Program year20252 payments
- Avanos MedicalProgram year20231 payment
- Abbott LaboratoriesProgram year20211 payment
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Opioid Agonist100%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 26 Oct 2026
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Use of radioprotector in rectal cancer
University of Nebraska Medical Center
FY2026$603,952R01CA255618 - Use of radioprotector in rectal cancer
University of Nebraska Medical Center
FY2025$603,951R01CA255618 - Dynamic Double Network Hydrogel for Generating Pancreatic Organoids from InducedPluripotent Stem Cells
Purdue University
FY2025$442,142R01DK127436
Congress activity
Updated 26 Oct 2026
60 congress contributions (2009–2024) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- WDR4 as a potential indicator of clinical prognosis and immunotherapy in hepatocellular carcinoma.
ASCO Annual Meeting
ASCO2024Presenting authorOnline-only - Prognostic Value of Tumor Volume Reduction during Radiotherapy in Patients with Locally Advanced Cervical Cancer in Different Risk Groups
ASTRO Annual Meeting
ASTRO2023Presenting author - Effect of adding immunotherapy to standard of care on survival in patients with esophageal cancer: Analysis of NCDB database.
ASCO Annual Meeting
ASCO2022Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 26 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases.
Hepatic oncology
Article2024 - Combination Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer: A Review of Evidence.
Cancer medicine
Review2024 - Association of facility type with overall survival in patients with nonsurgically managed pancreatic cancer.
Future oncology (London, England)
Article2022
Most-cited works
by citation count (OpenAlex)- 01
- 02Marital Status and Survival in Pancreatic Cancer Patients: A SEER Based AnalysisArticle178 citations2011
- 03Biological determinants of radioresistance and their remediation in pancreatic cancerArticle124 citations2017
- 04Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyArticle104 citations2018
- 05MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic CancerArticle96 citations2017
Network
Updated 26 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 26 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nebraskamed.com ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nebraskamed.com ↗
- MD
PhD, MS (listed as Chi Lin, MD, PhD, MS)
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
Editorial & leadership roles
journal and society appointments- Member
American Society for Therapeutic Radiology and Oncology
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗ - Member
American College of Radiation Oncology
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗ - Member
American Society of Clinical Oncology
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗ - Member
American College of Radiology
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nebraskamed.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Julie Vose, MD
University of Nebraska Medical Center
Kathleen Moore, MD
University of Nebraska Medical Center
Ted Mikuls, MD
University of Nebraska Medical Center
Roslyn Mannon, MD
University of Nebraska Medical Center
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH